Plus Therapeutics Appoints Dr. Eric J. Daniels as Chief Development Officer

On April 9, 2026, Plus Therapeutics, Inc. announced the appointment of Eric J. Daniels, M.D., as Chief Development Officer, effective April 20, 2026. Dr. Daniels, age 53, joins from Kiora Pharmaceuticals, where he also served as Chief Development Officer. In his new role, Dr. Daniels will oversee the development and regulatory approval of the company's pharmaceutical pipeline. Under the terms of his employment agreement, Dr. Daniels will receive an initial annual base salary of $460,000 and a target annual bonus of 40% of his base salary. As an inducement to join, he was granted an option to purchase 20,000 shares of common stock, vesting over four years, and 20,000 restricted stock units (RSUs), vesting over three years. The agreement includes severance provisions providing for twelve months of base salary, a target bonus, and accelerated vesting of equity awards in the event of an involuntary termination. The company also entered into a standard indemnification agreement with Dr. Daniels.